Cutaquig FAQs

Frequently asked questions about cutaquig

General FAQs about cutaquig

FAQs about self-administering cutaquig

FAQs about IG products

icon-clip-board Created with Sketch.

What is PI?

Learn more about PI
References:
  1. Cutaquig® [package insert]. Lachen, Switzerland: Octapharma AG; 2018.
  2. Berman K. Safety, Efficacy, Tolerability, Advantages and Disadvantages of Intravenous and Subcutaneous Immune Globulin Therapy. Highlights from IG Living Teleconference. December 10, 2015. http://www.igliving.com/life-with-ig/teleconference/advantages-and-disadvantages-of-intravenous-and-subcutaneous-immune-globulin-therapy.html. Accessed April 25, 2019.
  3. Clinical Study Report SCGAM-01. Clinical Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability and safety of subcutaneous human immunoglobulin (octanorm 16.5%) in patients with primary immunodeficiency diseases. NCT01888484. June 2018. https://clinicaltrials.gov/ct2/show/NCT01888484. Accessed May 2, 2019.
  4. Kobayashi RH, Gupta S, Melamed I, et al. Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies. Front Immunol. 2019;10(40):1-12.
  5. McCormack PL. Immune globulin subcutaneous (human) 20% in primary immunodeficiency disorders. Drugs. 2012;72(8):1087-1097.
  6. Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277-287.